What does product — total collaboration revenue mean?

This metric represents the total revenue recognized from collaborative research, development, and licensing agreements specifically attributed to the company's product development segment. It reflects the financial value generated through partnerships where the company shares intellectual property or development responsibilities with other entities. Tracking this revenue stream is essential for evaluating the commercial success and market validation of the company's proprietary therapeutic pipeline.

Denali Therapeutics Inc. (DNLI) Product — Total collaboration revenue

Screener

Other product segments

Milestone Triggered

$25M—

Milestone Payment

$2.5M0.0%

Option Fee Payment

$2.5M+100%

Similar metrics at other companies

ESP

ESPRCollaboration revenue — Total Revenues

$36.71M+22.0%

SUPNCollaboration revenue (ZURZUVAE) — Total revenues

$27.64M—

CYTKCollaboration Revenues — Revenue

$3.29M+36.2%

EXELCollaboration — Total revenues

$55.67M+15.4%

NBIXCollaboration revenues — Total revenues

$3.5M-60.7%

PTH

PTHSLicense and collaboration revenues — Total Revenue

$241K—

Other financials

Income statement

See full

Revenue$3.6M—

Gross profit$3.5M—

Operating income-$130.5M+3.3%

Net income-$127.6M-2.8%

EPS (diluted)-$0.68+5.6%

Balance sheet

See full

Cash & equivalents$204.6M+41.8%

Total debt$37.7M-21.4%

Total equity$835.2M-18.7%

Total assets$1.2B-0.7%

Cash flow

See full

Operating cash flow-$97.0M-28.8%

CapEx$805.0K-81.2%

Free cash flow-$97.8M-22.9%

Valuation

See full

Market cap$3.92B+88.3%

Enterprise value$3.76B+89.0%

P/S1,089×+1,084×

Profitability

See full

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

See full

Return on equity-54.9%+34.3pp

Debt / equity0×0.0×

Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 4:08 PM EDT
Fiscal quarter: Q4 FY2026
Calendar quarter: Q4 2026
Accession: 0001714899-26-000097

The Company has no remaining performance obligations under the Biogen Collaboration Agreement, and therefore no contract liability remained on the Condensed Consolidated Balance Sheets as of June 30, 2026 or December 31, 2025. As of June 30, 2026, the Company had not recorded milestone revenue or product sales under the Biogen Collaboration Agreement.

Item 1. Financial Statements (Unaudited)

FAQ

What is Denali Therapeutics Inc.'s product — total collaboration revenue?: Denali Therapeutics Inc. (DNLI) reported product — total collaboration revenue of $0 in Q4 2026.
What does product — total collaboration revenue mean?: This metric represents the total revenue recognized from collaborative research, development, and licensing agreements specifically attributed to the company's product development segment. It reflects the financial value generated through partnerships where the company shares intellectual property or development responsibilities with other entities. Tracking this revenue stream is essential for evaluating the commercial success and market validation of the company's proprietary therapeutic pipeline.